When was Amunix founded?

Amunix was founded in 2006 and raised its 1st funding round 1 year after it was founded.

Where is Amunix located?

Amunix is headquartered in Mountain View, United States. It is registered at South San Franicsco,California.

How many employees does Amunix have?

As of Mar 01, 2026, the latest employee count at Amunix is 10 - 49.

Is Amunix a funded company?

Amunix is a funded company, having raised a total of $201M across 8 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 15, 2007.

When was the latest funding round of Amunix?

Amunix's latest funding was a $***** Series B round on Mar 04, 2021, with participation from 15 investors.

Where does Amunix rank among its competitors?

Amunix ranks 684th amongst 3803 active competitors, of which 1248 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Amunix?

Amunix's top competitors include Jazz Pharmaceuticals, BeiGene and Biogen. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Amunix - 2026 Company Profile, Funding & Competitors

Q: Is Amunix an acquired company?

Amunix got acquired by Sanofi on Dec 20, 2021.

Company Details

Developer of peptide-based therapeutics. The lead candidate AMX-818 is a masked T cell engager targeting HER2, a receptor tyrosine kinase expressed on a wide variety of solid tumors, others include Wave2 XPAT, Wve3 XPAT, IL12 XPAC, and others for immune disorders and cancers. The company's products are based on its proprietary XTEN half-life extension, XDC drug-conjugate delivery, and ProTIA pro-drug, bispecific T cell engager platform.

Website: amunix.com
Email ID: *****@amunix.com
Phone Number: +1 **********
Part Of
Registered Address: South San Franicsco,California

Key Metrics

Founded Year

2006

Location

Mountain View, United States

Stage

Acquired

Total Funding

$201M in 8 rounds

Latest Funding Round

Series B, Mar 04, 2021, $*****

Investors

Frazier Healthcare Partners & 19 more

Ranked

684^th among 3803 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Investment & Acquisitions

Diartis Pharmaceuticals

Similar Companies

Jazz Pharmaceuticals & 3637 more

Exit Details

Acquired by Sanofi (Dec 20, 2021)

View Amunix's full profile

Amunix is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Amunix Operating Inc. CIN: 271108708 , United States, Active	Dec 31, 1999	-	82 (As on Dec 31, 2021)	-

Amunix got acquired by Sanofi on Dec 20, 2021 at an acquisition amount of $*****.

Click here to take a look at Amunix's acquisition in detail

Amunix has raised a total funding of $201M over 8 rounds. Its first funding round was on Apr 15, 2007. Its latest funding round was a Series B round on Mar 04, 2021 for $*****. 15 investors participated in its latest round. Amunix has 20 institutional investors.

Here is the list of recent funding rounds of Amunix:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 04, 2021	7134223	Series B	2962392	8216596	7090788	8960054
Mar 04, 2020	3231115	Series A	9045577	8671890	3422754	Frazier Healthcare Partners & 7 more
2018	6747	Series A	9896	6433	Frazier Healthcare Partners	6279

Access funding benchmarks and valuations. Sign up today!

View details of Amunix's funding rounds and investors

Amunix's employee count trend

Amunix has 10 - 49 employees as of Mar 26. Here is Amunix's employee count trend over the years:

Uncover Amunix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Amunix include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of Amunix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
7th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
684th	Amunix 2006, Mountain View (United States), Acquired	Developer of peptide-based therapeutics	$201M	Bain Capital Life Sciences, ArrowMark Partners ... & 18 others	49/100